Research indicates that blood and cerebrospinal fluid tests provide relevant prognostic information for elderly patients, challenging the idea that aging makes these tests less useful.
CNSide Diagnostics has secured a national agreement with Elevance Health, expanding access to its CSF Tumor Cell Enumeration assay to 45.4 million more people in the US, Plus Therapeutics announced.
The test detect signs of colorectal cancer and precancerous growths using a home collection kit.
The whole-genome sequencing assay is now available for breast, colorectal, and renal cancers following new clinical study results.
The point-of-care assay provides results in 15 minutes and received a waiver for use in decentralized settings.
A simplified test of HDL's ability to remove cholesterol was associated with high-risk coronary plaques in a study of 61 patients.
As autoimmune and allergy test volumes rise, labs are prioritizing workflow standardization and structured testing pathways to ensure reliable results, according to Santhosh Nair, president of immunodiagnostics at Thermo Fisher Scientific.
The assay measures enzyme activity in plasma to help clinicians identify acute ischemic stroke, which is often missed by standard imaging.
The agreement will integrate a specific antibody into diagnostic tests for use on widely installed immunoassay systems.
Research suggests that only 12% of men receiving testosterone prescriptions underwent appropriate testing.
Elevated donor-derived cell-free DNA levels are linked to higher kidney transplant failure risk, suggesting earlier detection of allograft injury before loss of kidney function.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The BD BACTEC FXI Culture System reduces detection time for bloodstream infections by approximately three hours compared to previous models.